News
Valneva delivers additional data for COVID-19 booster vaccine
Following a clinical study, Valneva’s COVID-19 booster vaccine candidate, VLA2001, has yielded more data. A subset of participants received VLA2001 following two or three doses of the mRNA COVID-19 vaccine, with or without break-through infection among 25 to 50 participants per group.